AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29996892 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanting clinical-grade umbilical cord mesenchymal stem cells (UC-MSCs) loaded onto a degradable collagen scaffold
Number of subjects: 26
Study 29996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Low leisure-time physical activity
Number of subjects: 10038
Study 29996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Early increasing leisure-time physical activity
Number of subjects: 10038
Study 29996930 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and late decreasing leisure-time physical activity patterns
Number of subjects: 10038
Study 29996930 — intervention group
Group type: COMPARATOR
Intervention: High leisure-time physical activity
Number of subjects: 10038
Study 29997136 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg once daily
Number of subjects: 72
Study 29997136 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine starting dose of 5 mg/kg/day, decreasing to 3-3.5 mg/kg/day after 8 weeks
Number of subjects: 72
Study 29997136 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin
Number of subjects: 72
Study 29997136 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 72
Study 29997136 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin and Cyclosporine
Number of subjects: 72
Study 29997240 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2279
Study 29997240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2279
Study 29997287 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab
Number of subjects: 57
Study 29997287 — intervention group
Group type: EXPERIMENTAL
Intervention: nivolumab
Number of subjects: 57
Study 29997287 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX
Number of subjects: 57
Study 29997287 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX with nivolumab
Number of subjects: 57
Study 29997519 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 51
Study 29997519 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 51
Study 29997519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protocol (high-intensity exercise and resistance training)
Number of subjects: 51
Study 29997519 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 29997897 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 90 seconds
Number of subjects: 39
Study 29997897 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 120 seconds
Number of subjects: 39
Study 29997897 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (HC)
Number of subjects: 39
Study 29997898 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone delivered culturally appropriate Spanish behavioral intervention for OA management (18 sessions over 12 months)
Number of subjects: 15
Study 29997898 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider intervention with patient-specific OA treatment recommendations
Number of subjects: 15
Study 29998092 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight Intervention
Number of subjects: 0
Study 29998092 — intervention group
Group type: COMPARATOR
Intervention: Control Group (National Home Visiting Program)
Number of subjects: 0
Study 29998370 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day)
Number of subjects: 2007
Study 29998394 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted unilateral adrenalectomy
Number of subjects: 303
Study 30001986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lirilumab (3 mg/kg) as a single agent for lower-risk MDS patients
Number of subjects: 10
Study 30001986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lirilumab in combination with azacitidine (75 mg/m2) for higher-risk MDS patients
Number of subjects: 10
Study 30001986 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (both interventions)
Number of subjects: 10
Study 30001986 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events attributable to study drug
Number of subjects: 10
Study 30001987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day plus cetuximab 400 mg/m
Number of subjects: 22
Study 30001987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg/day
Number of subjects: 22
Study 30001987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg/day
Number of subjects: 22
Study 30001987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 22
Study 30001990 — intervention group
Group type: EXPERIMENTAL
Intervention: LTLD (liposomal targeted drug delivery) followed by focused ultrasound exposure
Number of subjects: 10
Study 30002102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA)
Number of subjects: 550
Study 30002102 — intervention group
Group type: COMPARATOR
Intervention: Technically operable disease (not undergoing surgery due to patient choice)
Number of subjects: 550
Study 30002102 — intervention group
Group type: COMPARATOR
Intervention: Technically operable disease (not undergoing surgery due to being unfit for surgery)
Number of subjects: 550
Study 30002102 — intervention group
Group type: COMPARATOR
Intervention: Inoperable disease
Number of subjects: 550
Study 30002106 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic breathlessness treatment
Number of subjects: 0
Study 30002106 — intervention group
Group type: COMPARATOR
Intervention: Chronic pain treatment
Number of subjects: 0
Study 30002113 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm (multisensor HF index and alert algorithm)
Number of subjects: 900
Study 30002113 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP measurement at enrollment (threshold of 1000 pg/mL)
Number of subjects: 900
Study 30002113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HeartLogic and NT-proBNP measurements
Number of subjects: 900
Study 30002483 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibition
Number of subjects: 0
Study 30002483 — intervention group
Group type: EXPERIMENTAL
Intervention: LDLR-mediated uptake of LTA and LPS
Number of subjects: 0
Study 30002483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial lipid uptake by hepatocytes
Number of subjects: 0
Study 30002832 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down DBT (3 months residential + 6 months outpatient)
Number of subjects: 84
Study 30002832 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down DBT
Number of subjects: 84
Study 30002832 — intervention group
Group type: COMPARATOR
Intervention: Outpatient DBT (12 months)
Number of subjects: 84
Study 30002832 — intervention group
Group type: COMPARATOR
Intervention: Outpatient DBT
Number of subjects: 84
Study 30002864 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab induction (200 mg initially and 100 mg at week 2) followed by maintenance (50 mg or 100 mg every 4 weeks until week 54)
Number of subjects: 205
Study 30002864 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab
Number of subjects: 205
Study 30002865 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA injections, tailored to individual presentation, with dosing generally in accordance with prescribing information.
Number of subjects: 0
Study 30002865 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA injections
Number of subjects: 0
Study 30003118 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX 335, an AAV8-based hemophilia B gene therapy vector designed to express the FIX Padua variant.
Number of subjects: 0
Study 30003118 — intervention group
Group type: EXPERIMENTAL
Intervention: Phage display technology to develop a Fab2 mini-antibody selectively binding to FIX Padua.
Number of subjects: 0
Study 30003350 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection (LLR)
Number of subjects: 45
Study 30003479 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Care Management
Number of subjects: 0
Study 30003479 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 30003563 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous hydrocortisone infusion (CSHI)
Number of subjects: 5
Study 30003579 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 30003579 — intervention group
Group type: COMPARATOR
Intervention: Conventional analysis (assumed treatment effect on mean only)
Number of subjects: 0
Study 30003675 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cytology
Number of subjects: 3556
Study 30003675 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cytology combined with imaging (CTU)
Number of subjects: 3556
Study 30003675 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cytology combined with imaging (RBUS)
Number of subjects: 3556
Study 30003675 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk cancer detection
Number of subjects: 3556
Study 30003675 — intervention group
Group type: EXPERIMENTAL
Intervention: False positive cytology results
Number of subjects: 3556
Study 30003996 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by consolidative radiation therapy (CRT)
Number of subjects: 29
Study 30004611 — intervention group
Group type: EXPERIMENTAL
Intervention: DMDD/HD
Number of subjects: 116
Study 30004611 — intervention group
Group type: EXPERIMENTAL
Intervention: DMDD
Number of subjects: 116
Study 30004611 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 116
Study 30004611 — intervention group
Group type: COMPARATOR
Intervention: DMDD/LD
Number of subjects: 116
Study 30004628 — intervention group
Group type: EXPERIMENTAL
Intervention: TGFβ1
Number of subjects: 851
Study 30004628 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of miR-128-3p
Number of subjects: 851
Study 30004628 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of ETS1
Number of subjects: 851
Study 30004820 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV-infected plasma cells (EBV+ cells)
Number of subjects: 99
Study 30004820 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV+ plasma cells (PCs)
Number of subjects: 99
Study 30004820 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron microscopy-based experiments
Number of subjects: 99
Study 30005011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART
Number of subjects: 12
Study 30005555 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous or allogeneic mesenchymal stem cells in DCM patients
Number of subjects: 79
Study 30005555 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous or allogeneic mesenchymal stem cells in ICM patients
Number of subjects: 79
Study 30005555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapy in both DCM and ICM patients
Number of subjects: 79
Study 30005622 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS)
Number of subjects: 308
Study 30005622 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission (planned vs. unplanned)
Number of subjects: 308
Study 30005622 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU resources and mortality measures
Number of subjects: 308
Study 30005636 — intervention group
Group type: EXPERIMENTAL
Intervention: Native T1-mapping
Number of subjects: 50
Study 30005636 — intervention group
Group type: EXPERIMENTAL
Intervention: T11SD
Number of subjects: 50
Study 30005636 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 in regions-of-interest defined as scar
Number of subjects: 50
Study 30005636 — intervention group
Group type: COMPARATOR
Intervention: Relative difference between remote myocardium and regions defined as scar
Number of subjects: 50
Study 30005640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision
Number of subjects: 52
Study 30005640 — intervention group
Group type: COMPARATOR
Intervention: Periumbilical incision
Number of subjects: 52
Study 30005644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Neu2000 (2.75 g)
Number of subjects: 210
Study 30005644 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Neu2000 (5.25 g)
Number of subjects: 210
Study 30005644 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 210
Study 30005648 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-controlled nebulizer
Number of subjects: 40
Study 30005648 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic nebulizer
Number of subjects: 40
Study 30005648 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with asthma
Number of subjects: 40
Study 30005663 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive Intervention Strategy (Phase 2)
Number of subjects: 2817
Study 30005663 — intervention group
Group type: COMPARATOR
Intervention: Phase 1 (Control)
Number of subjects: 2817
Study 30005663 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 (with multiple partners)
Number of subjects: 2817
Study 30005663 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 (adjusted for age)
Number of subjects: 2817
Study 30006030 — intervention group
Group type: EXPERIMENTAL
Intervention: miPlan app
Number of subjects: 207
Study 30006030 — intervention group
Group type: COMPARATOR
Intervention: Control (clinic visit alone)
Number of subjects: 207
Study 30006326 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (weekly SMS messages including medical information, compliance importance, appointment reminders)
Number of subjects: 2359
Study 30006328 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device resting heart rate (WD-rHR)
Number of subjects: 40
Study 30006328 — intervention group
Group type: COMPARATOR
Intervention: On-site resting heart rate (on-site rHR)
Number of subjects: 40
Study 30006328 — intervention group
Group type: COMPARATOR
Intervention: Hyperthyroidism Symptom Scale
Number of subjects: 40
Study 30006330 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT ≥12-month group (n=1776)
Number of subjects: 2082
Study 30006330 — intervention group
Group type: COMPARATOR
Intervention: DAPT <12-month group (n=306)
Number of subjects: 2082
Study 30006490 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM (n=95)
Number of subjects: 322
Study 30006490 — intervention group
Group type: COMPARATOR
Intervention: Patients without DM (n=227)
Number of subjects: 322
Study 30006493 — intervention group
Group type: COMPARATOR
Intervention: Complement fragment Ba levels in patients with CKD and post-kidney transplant CKD.
Number of subjects: 90
Study 30006493 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Ba levels in patients with CKD.
Number of subjects: 90
Study 30006493 — intervention group
Group type: COMPARATOR
Intervention: Factor D levels in plasma microparticles of patients with CKD.
Number of subjects: 90
Study 30006493 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma microparticles isolated from patients with CKD containing factor D.
Number of subjects: 90
Study 30006616 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA-enriched lipid emulsions (Omegaven, Fresenius-Kabi, Germany) for 5 days postoperatively
Number of subjects: 108
Study 30006616 — intervention group
Group type: COMPARATOR
Intervention: Structolipid alone (control group) for 5 days postoperatively
Number of subjects: 108
Study 30006729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 87
Study 30006729 — intervention group
Group type: EXPERIMENTAL
Intervention: Native Hawaiian or Other Pacific Islander (NHOPI)
Number of subjects: 87
Study 30006729 — intervention group
Group type: EXPERIMENTAL
Intervention: Older women ages 32-39 years
Number of subjects: 87
Study 30006729 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who took vitamins while breastfeeding
Number of subjects: 87
Study 30007443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide-only maintenance
Number of subjects: 601
Study 30007443 — intervention group
Group type: EXPERIMENTAL
Intervention: Any maintenance
Number of subjects: 601
Study 30007443 — intervention group
Group type: COMPARATOR
Intervention: No maintenance
Number of subjects: 601
Study 30007480 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry (IC) measured resting energy expenditure (REE)
Number of subjects: 126
Study 30007480 — intervention group
Group type: COMPARATOR
Intervention: Harris-Benedict equation for REE
Number of subjects: 126
Study 30007480 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory quotient (RQ)
Number of subjects: 126
Study 30007558 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting intra-abdominal and intermuscular fat
Number of subjects: 0
Study 30007558 — intervention group
Group type: COMPARATOR
Intervention: Healthy, age-matched controls
Number of subjects: 0
Study 30007765 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated programme with 28 home visits from coaches over a 6-month period
Number of subjects: 70
Study 30007765 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 70
Study 30007783 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolic protection devices
Number of subjects: 0
Study 30007783 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30007924 — intervention group
Group type: EXPERIMENTAL
Intervention: Household Model intervention with community health workers (CHWs) reassigned to households.
Number of subjects: 21800
Study 30008789 — intervention group
Group type: EXPERIMENTAL
Intervention: α-Tocopherol from natural sources
Number of subjects: 0
Study 30008789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30009185 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum administered intralymphatically
Number of subjects: 0
Study 30009185 — intervention group
Group type: COMPARATOR
Intervention: GAD-alum administered subcutaneously
Number of subjects: 0
Study 30009214 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple simultaneous microelectrode recordings
Number of subjects: 60
Study 30009214 — intervention group
Group type: COMPARATOR
Intervention: Single sequential microelectrode recordings
Number of subjects: 60
Study 30009213 — intervention group
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA (up to 200 U, single open-label intramuscular dose)
Number of subjects: 37
Study 30009275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) consisting of 10 telephone-based sessions with an accompanying workbook
Number of subjects: 500
Study 30009275 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga consisting of 10 weeks of group yoga classes (twice a week) modified for older adults
Number of subjects: 500
Study 30009275 — intervention group
Group type: COMPARATOR
Intervention: Preference trial (participants choose the intervention)
Number of subjects: 500
Study 30009275 — intervention group
Group type: COMPARATOR
Intervention: Randomized trial (participants are randomized to one of the two interventions)
Number of subjects: 500
Study 30009815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (35 g) dissolved in 300 mL water
Number of subjects: 2042
Study 30009815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (50 g) dissolved in 300 mL water
Number of subjects: 2042
Study 30009894 — intervention group
Group type: EXPERIMENTAL
Intervention: pEYS606 (non-viral gene therapy)
Number of subjects: 0
Study 30009926 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency/short duration deliberate practice PPV training and post-event video-based debriefings
Number of subjects: 227
Study 30009926 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-implementation)
Number of subjects: 227
Study 30010022 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics ophthalmoscopy (AOO)
Number of subjects: 0
Study 30010028 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Contraction Fraction (MCF) <25%
Number of subjects: 530
Study 30010028 — intervention group
Group type: COMPARATOR
Intervention: Ejection Fraction (EF) dichotomized at 50%
Number of subjects: 530
Study 30010028 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model combining MCF with systolic blood pressure, renal function, NYHA functional class, and health status
Number of subjects: 530
Study 30010121 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CerC18:0 concentrations
Number of subjects: 60
Study 30010121 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CerC18:0/SM18:0 ratio
Number of subjects: 60
Study 30010630 — intervention group
Group type: EXPERIMENTAL
Intervention: aHLH treatment
Number of subjects: 244
Study 30010630 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (undetected aHLH)
Number of subjects: 244
Study 30010630 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (ICU patients with hyperferritinemia)
Number of subjects: 244
Study 30010630 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (overall mortality)
Number of subjects: 244
Study 30010775 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-fluorodeoxyglucose positron emission tomography (PET) scanning
Number of subjects: 832
Study 30010775 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow biopsy
Number of subjects: 832
Study 30010891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab treatment for at least 6 months
Number of subjects: 1684
Study 30010906 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue vaccination (TV003)
Number of subjects: 40
Study 30010906 — intervention group
Group type: COMPARATOR
Intervention: Natural infection (DENV-3)
Number of subjects: 40
Study 30011285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Atrial Swirl Sign (RASS) assessed by residents after a short training session
Number of subjects: 100
Study 30011285 — intervention group
Group type: COMPARATOR
Intervention: Post-procedural chest radiograph (CXR) as gold standard
Number of subjects: 100
Study 30012100 — intervention group
Group type: EXPERIMENTAL
Intervention: APC mutations associated with classic FAP
Number of subjects: 150
Study 30012100 — intervention group
Group type: COMPARATOR
Intervention: APC mutations associated with attenuated FAP
Number of subjects: 150
Study 30012100 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 150